23andMe’s genetic information database is its goldmine

January 9, 2015 6:25 PM

4 0

Home gene-testing kit producer 23andMe has signed a deal worth US$60m with Genentech to analyze 3,000 Parkinson’s disease genomes and is on the way to expand its business model to the pharmaceutical industry. This is the first of several deals 23andMe is expected to strike with major pharmaceutical companies soon.

Earlier, the US Food and Drug Administration (FDA) made efforts to shut down the company for deemed violation of the law as it provided providing genetic testing to show whether a person had a predisposition to certain cancers and other diseases.

Also read: Apple tells feds ‘new entrants’ to auto industry should get same testing rights as incumbents

Read more

To category page

Loading...